Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

In a correspondence to Nature Medicine, a team of Oxford-led academics describe upcoming new guidelines to improve the reporting of early clinical stage (or first-with-human) evaluation of decision support systems driven by artificial intelligence.

Red light with silhouette of a man

As an increasing number of clinical decision-support systems driven by artificial intelligence progress from development to implementation, better guidance on the reporting of human factors (ergonomics) and early-stage clinical evaluation is needed.

Therefore, Dr Baptiste Vasey and Professor Peter McCulloch from the Nuffield Department of Surgical Sciences, together with a steering group of experts in the fields of machine learning, human factors, and guidelines development from Oxford University and other universities in the UK and abroad, aim to develop new guidelines to improve the reporting of the early-stage clinical evaluation of AI-based decision support systems.

“We are convinced that human clinicians should and will remain at the centre of patient care, and therefore aiming to improve the way in which AI-based clinical decision support systems are evaluated when used to enhance rather than replace human intelligence. A critical phase of this process is when such systems are assessed when first used by clinicians in real life settings,” says Dr Vasey.

The article outlines a Delphi process, comprising two rounds of experts’ feedback and one consensus meeting, and the rationale for the new Developmental and Exploratory Clinical Investigation of Decision support systems based on Artificial Intelligence (DECIDE-AI) guidelines being developed. The authors hope to address some of the important issues hindering the translation from in silico algorithm development to clinical impact.

Read the full story on the Nuffield Department of Surgical Sciences website

Similar stories

Prestigious award for Oxford professor's diabetes work

A University of Oxford professor has been awarded the 2021 EASD-Novo Nordisk Foundation Prize for Excellence for his decades of effort to understand, prevent and combat type 1 diabetes.

Wellcome accolades for Dr Douglas

Dr Alexander (Sandy) Douglas, an investigator at the Jenner Institute, Nuffield Department of Medicine, has recently received two prestigious Wellcome accolades.

FOCUS4: a flagship trial in colorectal cancer

Professor Tim Maughan (Department of Oncology) outlines the flagship work of the FOCUS4 trials, whose results were presented last weekend at the European Society of Medical Oncology (ESMO) annual meeting

Oxford and Oracle partner to speed identification of COVID-19 variants

The fast spread of the highly infectious Delta variant underscores the need for faster identification of COVID-19 mutations. Uniting governments and medical communities in this challenge, the University of Oxford and Oracle’s Global Pathogen Analysis System (GPAS) is now being used by organizations on nearly every continent. Institutions using the platform include: the University of Montreal Hospital Centre Research Centre, the Institute of Public Health Research of Chile, the Oxford University Clinical Research Unit in Vietnam, the Institute of Clinical Pathology and Medical Research – New South Wales Pathology, and Oxford Nanopore Technologies. GPAS is also now part of the Public Health England New Variant Assessment Platform.

Vaccinated groups at highest risk of Covid-19 hospitalisation and death identified using new QCovid tool

Researchers from the University of Oxford have today reported on findings on the vaccinated people who are at greatest risk from severe Covid-19 leading to hospitalisation or death from 14 days post the second dose vaccination, when substantial immunity should be expected.